Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
    • COVID-19 arrow_forward
  • Pipeline
    • Overview arrow_forward
    • ADP-A2M4 arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • ADP-A2AFP arrow_forward
    • ADP-A2M10 arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clincial Trials arrow_forward
    • Cancer Info arrow_forward
    • Cancer Immunotherapy Month arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
  • Investors & Media
    • Overview arrow_forward
    • News & Events arrow_forward
    • Annual Shareholder Meeting arrow_forward
    • Company Info arrow_forward
    • Financial Info arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
    • Governance arrow_forward
    • Media arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • U.S. Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Annual Shareholder Meeting
  • Company Info
    • Overview
    • Leadership Team
    • Board of Directors
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Media
  • News & Media

  • Press Releases
  • Presentations
  • Events
Nov 08, 2016 8:00am EST

Adaptimmune to Present Three Posters at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)

Nov 07, 2016 1:45pm EST

Adaptimmune to Report Third Quarter 2016 Financial Results on November 10, 2016

Oct 27, 2016 4:00pm EDT

Adaptimmune Announces Board Changes

Oct 27, 2016 10:05am EDT

Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

Oct 18, 2016 8:00am EDT

Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10

Oct 12, 2016 9:15am EDT

Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer

Oct 09, 2016 10:00am EDT

Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress

Oct 05, 2016 4:30pm EDT

Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress

Sep 26, 2016 7:30am EDT

MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers

Sep 19, 2016 7:30am EDT

Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization

RSS
  • Prev
  • 1...
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms
Linedin Twitter Youtube
© 2021 Adaptimmune Therapeutics plc. All Rights Reserved.